Review
Biochemistry & Molecular Biology
Dominika Bebnowska, Rafal Hrynkiewicz, Ewelina Grywalska, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Iwona Smarz-Widelska, Stanislaw Gozdz, Jacek Rolinski, Paulina Niedzwiedzka-Rystwej
Summary: The article discusses the prognostic value of immune system components in patients with multiple myeloma to aid in the development of new diagnostic and therapeutic directions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Craig T. Wallington-Beddoe, Rachel L. Mynott
Summary: New approaches are needed to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, however, insufficient information currently exists to utilize biomarkers to tweak treatment. With the increasing complexity of drug classes used to treat multiple myeloma, clinically useful biomarkers are crucial in guiding personalized patient management.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Cell Biology
Ignacio J. Cardona-Benavides, Cristina de Ramon, Norma C. Gutierrez
Summary: This review summarizes the main genetic abnormalities in multiple myeloma and their therapeutic approaches, highlighting certain mutations as potential targets for personalized medicine.
Article
Hematology
Hadiyah Y. Audil, Joselle M. Cook, Patricia T. Greipp, Prashant Kapoor, Linda B. Baughn, Angela Dispenzieri, Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, David Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Eli Muchtar, Mustaqeem Siddiqui, Wilson Gonsalves, Yi Lisa Hwa, Nelson Leung, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, Rhett P. Ketterling, S. Vincent Rajkumar, Shaji K. Kumar
Summary: Acquisition of 1q22 gain in multiple myeloma patients is associated with reduced overall survival. Presence of high-risk FISH abnormalities at baseline increases the risk of acquiring 1q22 gain.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Immunology
Tiantian Ma, Jing Shi, Yuxia Xiao, Tianyue Bian, Jincheng Wang, Lingyun Hui, Mengchang Wang, Huasheng Liu
Summary: This study investigated the expression level of BCMA in the bone marrow of multiple myeloma patients and found correlations with disease stability, disease type, and certain prognostic factors, but not with age and serum creatinine levels.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Jill Corre, Nikhil C. Munshi, Herve Avet-Loiseau
Summary: Although therapeutic strategies for multiple myeloma patients have been adapted based on age and comorbidities, high-risk patients still lack efficient treatment options. There is an urgent need to revise the current definition of risk in order to provide more effective drug combinations for these patients.
Article
Oncology
Nadine H. Abdallah, Alexandra N. Smith, Susan Geyer, Moritz Binder, Patricia T. Greipp, Prashant Kapoor, Angela Dispenzieri, Morie A. Gertz, Linda B. Baughn, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Yi L. Hwa, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Summary: This study aimed to estimate conditional survival (CS) at 1-8 years from diagnosis and investigate the impact of baseline prognostic factors on CS in multiple myeloma (MM) patients. A retrospective study including 2556 MM patients diagnosed between 2004 and 2019 was conducted. The findings revealed that age ≥65 and proteasome inhibitor+immunomodulatory-based induction were associated with decreased and increased survival, respectively, retained at 5 years. High-risk cytogenetic factors had a significant adverse impact at 1 and 3 years but not 5 years. Chromosome 17 abnormality was associated with decreased survival only at 1 year. Overall, the 5-year CS remained stable at 1-5 years from diagnosis among MM patients, and the prognostic impact of high-risk cytogenetic factors decreased with additional years survived.
BLOOD CANCER JOURNAL
(2023)
Review
Immunology
Leora S. Boussi, Zachary M. Avigan, Jacalyn Rosenblatt
Summary: Despite advances in treatment for multiple myeloma, understanding the mechanisms of immune evasion and resistance to therapy is critical for developing more effective treatments. Cellular adoptive therapy, particularly CAR T cell therapy, has shown promising results in refractory cases and may be a viable option for treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Romika Kumari, Muntasir Mamun Majumder, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman
Summary: This study evaluated the biological significance of esterase expression in multiple myeloma (MM) by analyzing gene expression profiling and genomic variants in patients with newly diagnosed MM (NDMM) or relapsed/refractory MM (RRMM). High or low expression of specific esterases in MM, such as UCHL5, SIAE, ESD, PAFAH1B3, PNPLA4, and PON1, were significantly altered as patients progressed from NDMM to RRMM. Certain esterases, like OVCA2, PAFAH1B3, SIAE, USP4, and PCED1B, were identified as poor prognostic markers, suggesting their potential role in myeloma biology.
BRITISH JOURNAL OF CANCER
(2021)
Article
Cell Biology
Limei Zhang, Shuzhao Chen, Weida Wang, Yun Wang, Yang Liang
Summary: A predictive model based on six clinical variables was developed to predict the survival of patients with primary extramedullary multiple myeloma (EMM), showing good prognostic performance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Cong Deng, Chaozeng Si, Xu Ye, Qiang Zhou, Tiansheng Zeng, Zeyong Huang, Wenhui Huang, Pei Zhu, Qingfu Zhong, Zhihua Wu, Huoyan Zhu, Qing Lin, Wenjuan Zhang, Lin Fu, Yongjiang Zheng, Tingting Qian
Summary: The study demonstrated that FSCN1 was significantly down-regulated in MM and high expression of FSCN1 and FSCN2 were associated with longer overall survival (OS) in MM patients. FSCN1 and FSCN2 could serve as favorable prognostic factors for predicting clinical outcomes in MM, and their combination could effectively predict longer event-free survival (EFS) and OS.
Article
Medicine, General & Internal
Jing Wang, Na Shen, Xuxing Shen, Run Zhang, Yuanyuan Jin, Jianyong Li, Lijuan Chen
Summary: This study assessed the prognostic impact of extramedullary disease (EMD) on newly diagnosed multiple myeloma (NDMM) patients and developed a risk model based on EMD. The results showed that the type of EMD and treatment method have a significant impact on patients' survival rates. By establishing a prognostic model, we are able to provide individualized survival estimates for NDMM patients.
ANNALS OF MEDICINE
(2023)
Article
Oncology
JingSong He, XiaoYan Yue, DongHua He, Yi Zhao, Yang Yang, GaoFeng Zheng, Enfan Zhang, XiaoYan Han, WenJun Wu, Li Yang, Jing Chen, Zhen Cai
Summary: This study found that multiple sites of EMB and/or EME are independent poor prognostic factors for newly diagnosed MM patients treated with bortezomib-based regimens, while a single site of EMB does not affect patients' survival. Multiple sites of EMB and/or EME are prognostic predictors affecting PFS and OS in newly diagnosed MM patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Christelle Colin Leitzinger, Leyla Shune, Alexandria Shrewsbury, Rebecca Gonzalez, Douglas W. Sborov, Charlotte Wagner, Danai Dima, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher Ferreri, Aimaz Afrough, Ankit Kansagra, Peter Voorhees, Rachid Baz, Jack Khouri, Melissa Alsina, Joseph McGuirk, Frederick L. Locke, Krina K. Patel
Summary: A retrospective analysis showed that the safety and efficacy of standard-of-care ide-cel therapy in RRMM patients were similar to those seen in the phase II KarMMa trial, despite most patients not meeting the trial eligibility criteria.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Keiichi Akizuki, Hitoshi Matsuoka, Takanori Toyama, Ayako Kamiunten, Masaaki Sekine, Kotaro Shide, Takuro Kameda, Noriaki Kawano, Kouichi Maeda, Masanori Takeuchi, Hiroshi Kawano, Seiichi Sato, Junzo Ishizaki, Yuki Tahira, Haruko Shimoda, Tomonori Hidaka, Kiyoshi Yamashita, Yoko Kubuki, Kazuya Shimoda
Summary: The study surveyed real-world data of 284 patients newly diagnosed with multiple myeloma in Miyazaki Prefecture between 2010 and 2018. The use of bortezomib-containing regimens as initial treatment was common, and 80% of patients were treated with novel agents. Patients who responded with partial response (PR) or better to initial treatment had a favorable prognosis for time to next treatment (TTNT). Independent prognostic factors for overall survival (OS) included ISS stage I/II disease, PR or better response to initial treatment, and autologous stem cell transplantation (ASCT).
JOURNAL OF CLINICAL MEDICINE
(2021)
Letter
Hematology
Jonathan I. Sive, Andrew Feber, Dean Smith, John Quinn, Stephan Beck, Kwee Yong
BRITISH JOURNAL OF HAEMATOLOGY
(2016)
Letter
Hematology
Dean Smith, Elena Armenteros, Laura Percy, Madhu Kumar, Anna Lach, Gaelle Herledan, Matthew Stubbs, Julian Downward, Kwee Yong
BRITISH JOURNAL OF HAEMATOLOGY
(2015)
Letter
Hematology
Dean Smith, Clemency Stephenson, Laura Percy, Anna Lach, Steve Chatters, Helena Kempski, Kwee Yong
BRITISH JOURNAL OF HAEMATOLOGY
(2015)
Article
Oncology
Joe Lee, Dean Smith, Neil Rabin, Jeffrey Tobias, Kwee Yong
HEMATOLOGICAL ONCOLOGY
(2016)
Article
Hematology
Dean Smith, David Mann, Kwee Yong
BRITISH JOURNAL OF HAEMATOLOGY
(2016)
Letter
Oncology
M. Chin, J. I. Sive, C. Allen, C. Roddie, S. J. Chavda, D. Smith, P. Blombery, K. Jones, G. L. Ryland, R. Popat, A. Rismani, S. D'Sa, N. Rabin, R. E. Gale, K. L. Yong
BLOOD CANCER JOURNAL
(2017)
Article
Hematology
Nicolas Martinez-Calle, Sarah Hartley, Matthew Ahearne, Benjamin Kasenda, Amy Beech, Helen Knight, Constantine Balotis, Ben Kennedy, Simon Wagner, Martin J. S. Dyer, Dean Smith, Andrew K. McMillan, Fiona Miall, Mark Bishton, Christopher P. Fox
BRITISH JOURNAL OF HAEMATOLOGY
(2019)
Meeting Abstract
Oncology
Martin Grundy, Joanna Cull, Firas Al-Kaisi, Cathy Williams, Dean Smith, Claire Seedhouse
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2019)
Letter
Oncology
Rafael Gaiolla, Sarah Hartley, Amy Beech, Helen Knight, Dean Smith, Mark Bishton, Christopher P. Fox, Nicolas Martinez-Calle
HEMATOLOGICAL ONCOLOGY
(2021)
Editorial Material
Hematology
Rachel Fisken, Arieff Abuhassan, Dean Smith
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Jonathan Sive, Kirsty Cuthill, Hannah Hunter, Majid Kazmi, Guy Pratt, Dean Smith
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Letter
Hematology
Karthik Ramasamy, Ross Sadler, Sally Jeans, Sherin Varghese, Alison Turner, Jemma Larham, Nathanael Gray, Joe Barrett, Stella Bowcock, Gordon Cook, Chara Kyriakou, Dean Smith, Mark Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, Muhammad K. Javaid
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Meeting Abstract
Hematology
Kwee Yong, Kara-Louise Royle, Karthik Ramasamy, Christopher Parrish, Anna Hockaday, Samir Asher, Mark T. Drayson, Ruth M. de Tute, Matthew W. Jenner, Martin F. Kaiser, Guy Pratt, Jonathan Sive, Ceri Bygrave, Gordon Cook, Rakesh Popat, Dean Smith, Catherine Olivier, Lorna Barnard, Doina Levinte, Bryony Dawkins, Michael A. Chapman, Andrew D. Chantry, Graham Jackson, Sergio A. Quezada, Roger G. Owen, David Cairns
Meeting Abstract
Hematology
Melody Chin, Jonathan Sive, Christopher Allen, Claire Roddie, Selina J. Chavda, Dean Smith, Rakesh Popat, Ali Rismani, Shirley D'Sa, Neil Rabin, Rosemary E. Gale, Kwee L. Yong